Investigational drug · Phase 3
AG2304T
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hypercholesterolemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "AG2304T"
First trial start
2024
Sep 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AG2304T", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypercholesterolemia
Approved drugs for the same conditions: High cholesterol · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "AG2304T" as an intervention, largest first.
- A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304RPivotal-lookingCompleted
Ahn-Gook Pharmaceuticals Co.,LtdIndustry
NCT06717360 · 158 participants · Start Sep 30, 2024 · Primary completion Jul 10, 2025
Drug: AG2304T; AG2304R · For: Hypercholesterolemia
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Hypercholesterolemia
- SHR-1918Phase 37 trials
Beijing Suncadia Pharmaceuticals Co., Ltd · Homozygous Familial Hypercholesterolemia, Hyperlipidemia, Hypercholesterolemia
- AG2304RPhase 31 trial
Ahn-Gook Pharmaceuticals Co.,Ltd · Hypercholesterolemia
- FDC laroprovstatPhase 31 trial
AstraZeneca · Hypercholesterolemia
- VERVE-102LY4636581Phase 21 trial
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.